Skip to main content

Advertisement

SpringerLink
Log in

Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy

  • Biomarkers
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The aim of the study was to measure the diagnostic values of biomarkers of bacterial infection in idiopathic inflammatory myopathy (IIM) patients. The serum and clinical data of 82 IIM patients with/without bacterial infection were collected. Concentrations of soluble urokinase plasminogen activator receptor (suPAR), soluble triggering receptor expressed on myeloid cells 1 (sTREM-1), procalcitonin (PCT) and C-reactive protein (CRP) were measured in IIM patients and healthy controls. There were no significant differences in serum suPAR and sTREM-1 levels between healthy controls and non-infection IIM patients. Serum levels of suPAR, sTREM-1, PCT and CRP measured in this study were significantly higher in the IIM patient group with concurrent infection than in the non-infection IIM patient group (p < 0.05). The biomarker suPAR showed the highest diagnostic value with sensitivity, specificity, positive predictive value and negative predictive value of 81.6, 77.3, 75.6 and 82.9%, respectively. Combining suPAR negative and CRP negative to rule out bacterial infection in IIM patients provides a very high specificity of 97.4%. Both suPAR and CRP positive to confirm bacterial infection give the specificity of 90.9%. The inflammatory biomarkers suPAR, sTREM-1, PCT and CRP offer diagnostic accuracy in detecting bacterial infection in IIM patients. Particularly, suPAR is the most sensitive and specific biomarker to predict bacterial infection in IIM patients. Combination of suPAR and CRP serum levels provides an even better confirmation of bacterial infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ernste FC, Reed AM (2013) Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc 88:83–105. doi:10.1016/j.mayocp.2012.10.017

    Article  PubMed  Google Scholar 

  2. Torres C, Belmonte R, Carmona L, Gomez-Reino FJ, Galindo M, Ramos B et al (2006) Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 39:205–215. doi:10.1080/08916930600622603

    Article  PubMed  Google Scholar 

  3. Maldonado F, Patel RR, Iyer VN, Yi ES, Ryu JH (2012) Are respiratory complications common causes of death in inflammatory myopathies? An autopsy study. Respirology 17:455–460. doi:10.1111/j.1440-1843.2011.02103.x

    Article  PubMed  Google Scholar 

  4. Sciascia S, Ceberio L, Garcia-Fernandez C, Roccatello D, Karim Y, Cuadrado MJ (2012) Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers. Autoimmun Rev 12:157–163. doi:10.1016/j.autrev.2012.03.009

    Article  CAS  PubMed  Google Scholar 

  5. Cho SY, Choi JH (2014) Biomarkers of sepsis. Infect Chemother 46:1–12. doi:10.3947/ic.2014.46.1.1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Buhaescu I, Yood RA, Izzedine H (2010) Serum procalcitonin in systemic autoimmune diseases–where are we now? Semin Arthritis Rheum 40:176–183. doi:10.1016/j.semarthrit.2009.10.004

    Article  CAS  PubMed  Google Scholar 

  7. Bador KM, Intan S, Hussin S, Gafor AH (2012) Serum procalcitonin has negative predictive value for bacterial infection in active systemic lupus erythematosus. Lupus 21:1172–1177. doi:10.1177/0961203312450085

    Article  CAS  PubMed  Google Scholar 

  8. Wu JY, Lee SH, Shen CJ, Hsieh YC, Yo PH, Cheng HY et al (2012) Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum 64:3034–3042. doi:10.1002/art.34512

    Article  CAS  PubMed  Google Scholar 

  9. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K (1991) Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 266:1926–1933

    CAS  PubMed  Google Scholar 

  10. Ford JW, McVicar DW (2009) TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 21:38–46. doi:10.1016/j.coi.2009.01.009

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Gibot S (2005) Clinical review: role of triggering receptor expressed on myeloid cells-1 during sepsis. Crit Care 9:485–489. doi:10.1186/cc3732

    Article  PubMed  PubMed Central  Google Scholar 

  12. Bouchon A, Facchetti F, Weigand MA, Colonna M (2001) TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410:1103–1107. doi:10.1038/35074114

    Article  CAS  PubMed  Google Scholar 

  13. Prucha M, Bellingan G, Zazula R (2015) Sepsis biomarkers. Clin Chim Acta 440:97–103. doi:10.1016/j.cca.2014.11.012

    Article  CAS  PubMed  Google Scholar 

  14. Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ et al (2012) Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med 38:1418–1428. doi:10.1007/s00134-012-2613-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Zhang J, She D, Feng D, Jia Y, Xie L (2011) Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflect sepsis severity and can predict prognosis: a prospective study. BMC Infect Dis 11:53. doi:10.1186/1471-2334-11-53

    Article  PubMed  PubMed Central  Google Scholar 

  16. Jiyong J, Tiancha H, Wei C, Huahao S (2009) Diagnostic value of the soluble triggering receptor expressed on myeloid cells-1 in bacterial infection: a meta-analysis. Intensive Care Med 35:587–595. doi:10.1007/s00134-008-1333-z

    Article  PubMed  Google Scholar 

  17. Gibot S, Kolopp-Sarda MN, Bene MC, Cravoisy A, Levy B, Faure GC et al (2004) Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 141:9–15

    Article  CAS  PubMed  Google Scholar 

  18. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347. doi:10.1056/NEJM197502132920706

    Article  CAS  PubMed  Google Scholar 

  19. Furst DE, Amato AA, Iorga SR, Gajria K, Fernandes AW (2012) Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 45:676–683. doi:10.1002/mus.23302

    Article  PubMed  Google Scholar 

  20. Murray SG, Schmajuk G, Trupin L, Lawson E, Cascino M, Barton J et al (2015) A population-based study of infection-related hospital mortality in patients with dermatomyositis/polymyositis. Arthritis Care Res (Hoboken) 67:673–680. doi:10.1002/acr.22501

    Article  Google Scholar 

  21. Yu J, Xu B, Huang Y, Zhao J, Wang S, Wang H et al (2014) Serum procalcitonin and C-reactive protein for differentiating bacterial infection from disease activity in patients with systemic lupus erythematosus. Mod Rheumatol 24:457–463. doi:10.3109/14397595.2013.844391

    Article  CAS  PubMed  Google Scholar 

  22. Scire CA, Cavagna L, Perotti C, Bruschi E, Caporali R, Montecucco C (2006) Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol 24:123–128

    CAS  PubMed  Google Scholar 

  23. Sato H, Tanabe N, Murasawa A, Otaki Y, Sakai T, Sugaya T et al (2012) Procalcitonin is a specific marker for detecting bacterial infection in patients with rheumatoid arthritis. J Rheumatol 39:1517–1523. doi:10.3899/jrheum.111601

    Article  CAS  PubMed  Google Scholar 

  24. Chen DY, Chen YM, Ho WL, Chen HH, Shen GH, Lan JL (2009) Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still’s disease. Ann Rheum Dis 68:1074–1075. doi:10.1136/ard.2008.098335

    Article  PubMed  Google Scholar 

  25. Moosig F, Csernok E, Reinhold-Keller E, Schmitt W, Gross WL (1998) Elevated procalcitonin levels in active Wegener’s granulomatosis. J Rheumatol 25:1531–1533

    CAS  PubMed  Google Scholar 

  26. Kim HA, Jeon JY, An JM, Koh BR, Suh CH (2012) C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. J Rheumatol 39:728–734. doi:10.3899/jrheum.111044

    Article  CAS  PubMed  Google Scholar 

  27. Liu W, Sigdel KR, Wang Y, Su Q, Huang Y, Zhang YL et al (2015) High Level Serum Procalcitonin Associated Gouty Arthritis Susceptibility: from a Southern Chinese Han Population. PLoS ONE 10:e0132855. doi:10.1371/journal.pone.0132855

    Article  PubMed  PubMed Central  Google Scholar 

  28. Marioli A, Koupetori M, Raftogiannis M, Patrani M, Antonakos N, Pavlaki M et al (2014) Early changes of the kinetics of monocyte trem-1 reflect final outcome in human sepsis. BMC Immunol 15:585. doi:10.1186/s12865-014-0063-y

    Article  PubMed  PubMed Central  Google Scholar 

  29. Grover V, Pantelidis P, Soni N, Takata M, Shah PL, Wells AU et al (2014) A biomarker panel (Bioscore) incorporating monocytic surface and soluble TREM-1 has high discriminative value for ventilator-associated pneumonia: a prospective observational study. PLoS ONE 9:e109686. doi:10.1371/journal.pone.0109686

    Article  PubMed  PubMed Central  Google Scholar 

  30. Su L, Han B, Liu C, Liang L, Jiang Z, Deng J et al (2012) Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study. BMC Infect Dis 12:157. doi:10.1186/1471-2334-12-157

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Savva A, Raftogiannis M, Baziaka F, Routsi C, Antonopoulou A, Koutoukas P et al (2011) Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. J Infect 63:344–350. doi:10.1016/j.jinf.2011.07.016

    Article  PubMed  Google Scholar 

  32. Huttunen R, Syrjanen J, Vuento R, Hurme M, Huhtala H, Laine J et al (2011) Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 270:32–40. doi:10.1111/j.1365-2796.2011.02363.x

    Article  CAS  PubMed  Google Scholar 

  33. Kim J, Koh JK, Lee EY, Park JA, Kim HA, Lee EB et al (2009) Serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and pentraxin 3 (PTX3) as markers of infection in febrile patients with systemic lupus erythematosus. Clin Exp Rheumatol 27:773–778

    CAS  PubMed  Google Scholar 

  34. Qin DD, Song D, Huang J, Yu F, Zhao MH (2015) Plasma-soluble urokinase-type plasminogen activator receptor levels are associated with clinical and pathological activities in lupus nephritis: a large cohort study from China. Lupus 24:546–557. doi:10.1177/0961203314558857

    Article  CAS  PubMed  Google Scholar 

  35. Legany N, Toldi G, Distler JH, Beyer C, Szalay B, Kovacs L et al (2015) Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis. Clin Chem Lab Med 53:1799–1805. doi:10.1515/cclm-2015-0079

    Article  CAS  PubMed  Google Scholar 

  36. Manetti M, Rosa I, Milia AF, Guiducci S, Carmeliet P, Ibba-Manneschi L et al (2014) Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma? Ann Rheum Dis 73:1700–1709. doi:10.1136/annrheumdis-2013-203706

    Article  PubMed  Google Scholar 

  37. Enocsson H, Wettero J, Skogh T, Sjowall C (2013) Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. Transl Res 162:287–296. doi:10.1016/j.trsl.2013.07.003

    Article  CAS  PubMed  Google Scholar 

  38. Pliyev BK, Menshikov MY (2010) Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis. Inflammation 33:1–9. doi:10.1007/s10753-009-9152-0

    Article  CAS  PubMed  Google Scholar 

  39. Kaya S, Koksal I, Mentese A, Sonmez M, Sumer A, Yildirim SS et al (2013) The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies. Int J Infect Dis 17:e1056–e1059. doi:10.1016/j.ijid.2013.04.004

    Article  CAS  PubMed  Google Scholar 

  40. Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A et al (2011) Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 15:R63. doi:10.1186/cc10037

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by Hunan Provincial Natural Science Foundation of China (Grant No. 12JJ3106), Hunan Development and Reform Commission of China (Grant No.[2012] 1493) and Central South University of China (Grant No. 2012QNZT106).

Author information

Authors and Affiliations

  1. Department of Rheumatology and Immunology, Xiangya Hospital, Institute of Rheumatology and Immunology, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, People’s Republic of China

    Yizhi Xiao, Hui Luo, Bin Zhou, Xiaodan Dai, Jing Huang, Liping Duan, Yunhui You, Weiru Zhang, Hongjun Zhao, Yanli Xie, Yaou Zhou, Wangbin Ning, Tong Li, Sijia Liu, Honglin Zhu, Xiaoyun Xie, Ying Jiang, Shiyao Wu, Weijia He & Yisha Li

Authors
  1. Yizhi Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bin Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaodan Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jing Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liping Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yunhui You
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Weiru Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hongjun Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yanli Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yaou Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Wangbin Ning
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Tong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Sijia Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Honglin Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Xiaoyun Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Ying Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Shiyao Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Weijia He
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Yisha Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yisha Li.

Ethics declarations

Conflict of interest

Yizhi Xiao, Hui Luo, Bin Zhou, Xiaodan Dai, Jing Huang, Liping Duan, Yunhui You, Weiru Zhang, Hongjun Zhao, Yanli Xie, Yaou Zhou, Wangbin Ning, Tong Li, Sijia Liu, Honglin Zhu, Xiaoyun Xie, Ying Jiang, Xiaoyun Xie, Shiyao Wu, Weijia He and Yisha Li declare that they have no conflict of interest.

Human rights

All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki Declaration and its later amendments. Ethical approval was received from the Medical Ethics Committee of Xiangya Hospital, Central South University.

Informed consent

Written informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xiao, Y., Luo, H., Zhou, B. et al. Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy. Rheumatol Int 37, 585–592 (2017). https://doi.org/10.1007/s00296-016-3609-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-016-3609-x

Keywords

Search

Navigation